Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Companies Involved in Therapeutics Development
Landos Biopharma Inc
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles
BT-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-63 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-84 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NX-43 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones
Featured News & Press Releases
Aug 20, 2019: Landos Biopharma announces first patient dosed in global phase 2 trials of BT-11 in ulcerative colitis
May 15, 2019: Landos Biopharma announces publication of results from first-in-human phase 1 study of BT-11 in healthy volunteers
Mar 07, 2019: Landos Biopharma to present at upcoming investor conferences
Mar 05, 2019: Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11
Feb 21, 2019: Landos Biopharma announces publication supporting novel, dual mechanism of action for BT-11 in models of IBD
Jan 07, 2019: Landos Biopharma announces fil safety results from phase 1 study of BT-11 in healthy volunteers
Jul 12, 2018: Landos doses first subject cohort in Phase l trial of BT-11 for IBD
Jun 05, 2018: Landos Biopharma Announces Human Translatiol Results for Mechanisms of BT-11 in IBD at Digestive Disease Week 2018
May 01, 2018: Mechanistic and Human Translatiol Results for BT-11 in Models of IBD
Jun 05, 2014: European Patent issued advancing Biotherapeutics’ broad claims for treating and preventing Inflammation and Diabetes
May 19, 2014: BioTherapeutics awarded tiol Institutes of Health Small Business Innovation Research program award to advance novel therapy for IBD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type,, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Landos Biopharma Inc, H2 2019
Dormant Projects, H2 2019